Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies.

Autor: Marcus J Drake, Matthias Oelke, Robert Snijder, Monique Klaver, Klaudia Traudtner, Karin van Charldorp, Dominique Bongaerts, Philip Van Kerrebroeck

Publikováno v: PLoS ONE, Vol 12, Iss 2, p e0170726 (2017)

The emergence of urinary retention (UR), specifically acute urinary retention (AUR), has been a concern when treating men with lower urinary tract symptoms (LUTS) with antimuscarinic drugs.In NEPTUNE (12-week, double-blind), men (≥45 years) with LU

Externí odkaz: https://doaj.org/article/37b5fc45669145fd9abfc7ab68c14803

Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial

Autor: Philip, van Kerrebroeck, Christopher, Chapple, Ted, Drogendijk, Monique, Klaver, Roman, Sokol, Mark, Speakman, Klaudia, Traudtner, Marcus J, Drake, J, MacDermott

Publikováno v: European urology, 64(6), 1003-1012. Elsevier
European Urology, 64(6), 1003-1012. Elsevier

Background Storage symptoms are particularly bothersome in men with lower urinary tract symptoms (LUTS) but may not be adequately treated by α-blocker monotherapy. Objective To assess the efficacy and safety of a fixed-dose combination (FDC) of soli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ef5c958721716a9c66ecad3b6943d8f
https://doi.org/10.1016/j.eururo.2013.07.034

Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies

Autor: Philip Van Kerrebroeck, Monique Klaver, Klaudia Traudtner, Marcus J. Drake, Dominique Bongaerts, Robert Snijder, Karin Juliette van Charldorp, Matthias Oelke

Publikováno v: PLoS ONE
PLOS ONE, 12(2):0170726. Public Library of Science
PLoS ONE, Vol 12, Iss 2, p e0170726 (2017)
Drake, M J, Oelke, M, Snijder, R, Klaver, M, Traudtner, K, Van Charldorp, K, Bongaerts, D & Van Kerrebroeck, P 2017, ' Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS : A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies ', PLoS ONE, vol. 12, no. 2, e0170726 . https://doi.org/10.1371/journal.pone.0170726

Introduction The emergence of urinary retention (UR), specifically acute urinary retention (AUR), has been a concern when treating men with lower urinary tract symptoms (LUTS) with antimuscarinic drugs.Materials and methodsIn NEPTUNE (12-week, double

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3d698a13284c3ac5a50649ab49f987b
https://doi.org/10.1371/journal.pone.0170726

Reply from authors re: Apostolos Apostolidis. Male lower urinary tract symptoms: a riddle waiting to be solved. Eur Urol 2013;64:408-10: a rationale for combination antimuscarinic-α-blocker therapy for male lower urinary tract symptoms

Autor: Philip, Van Kerrebroeck, François, Haab, Javier C, Angulo, Viktor, Vik, Ferenc, Katona, Alberto, Garcia-Hernandez, Monique, Klaver, Klaudia, Traudtner, Matthias, Oelke

Publikováno v: European urology. 64(3)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::62a7e5147a3e225e383b902da92c0ea2
https://pubmed.ncbi.nlm.nih.gov/23731722

Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis

Autor: Christopher P. Day, Frederik Nevens, Dominique Larrey, Pierre Bedossa, Mihai Voiculescu, Lawrence Serfaty, Stephen D. Ryder, Gabriele I. Kirchner, Klaudia Traudtner, Jun Takeda, Liliana Preotescu, Guruprasad P. Aithal, Sven Francque, Victor de Lédinghen, Pavel Trunecka, Vlad Ratziu

Publikováno v: Clinical Gastroenterology and Hepatology
Clinical Gastroenterology and Hepatology, 2014, 12 (10), pp.1724-1730.e5. ⟨10.1016/j.cgh.2014.01.040⟩
Clinical gastroenterology and hepatology

International audience; Background & aims: ASP9831 is a phosphodiesterase-4 inhibitor developed to treat nonalcoholic steatohepatitis (NASH); it showed potent anti-inflammatory and antifibrotic effects in preclinical studies. We evaluated the efficac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d810f7b3b508bced1e41b5cee3f35cb6
https://doi.org/10.1016/j.cgh.2014.01.040